Vancouver, Canada

Aquinox Pharmaceuticals (Canada) Inc.

Calculating rank
USPTO Granted Patents = 9

% Expired Patents = 44.4

Forward Citations = 10

Loading Chart...
Loading Chart...

12 inventors (with patents filed for the assignee):

goldMedal Curtis Harwig (9 out of 32 patents)

silverMedal Lloyd F Mackenzie (8 out of 12 patents)

bronzeMedal Jeffery R Raymond (8 out of 14 patents)

4.  David Earl Bogucki (6 out of 32 patents)

5.  Jeremy D Pettigrew (6 out of 18 patents)

6.  Thomas B MacRury (5 out of 5 patents)

7.  Vladimir Khlebnikov (3 out of 6 patents)

8.  Rudong Shan (3 out of 6 patents)

9.  Ana Fernandez Casares (2 out of 8 patents)

10.  Mahesh Narayan Keregadde (1 out of 4 patents)

11.  Jeyaprakashnarayanan Seenisamy (1 out of 13 patents)

12.  Lakshindra Chetia (1 out of 1 patent)


9 patents:

Company Overview
Aquinox Pharmaceuticals (Canada) Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for urological and inflammatory conditions. Their lead product candidate is Rosiptor (AQX-1125), a small molecule oral therapy being evaluated for the treatment of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome. Aquinox Pharmaceuticals is dedicated to improving the lives of patients through research and development of new treatment options.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

9 Patents

#108 in Vancouver

#1,705 in Canada

Vancouver, CA
Vancouver, Canada
Forward Citations = 10

12 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aquinox Pharmaceuticals (Canada) Inc.. Retrieved from https://idiyas.com/company/aquinox-pharmaceuticals-canada

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…